Quick Takeaways
- Elanco Animal Health announced the phased US launch of Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody injection approved for the treatment of canine allergic dermatitis and canine atopic dermatitis with no age or weight restrictions
- Befrena is administered as an in-clinic injection and begins controlling itch within 24 hours by neutralizing IL-31, a cytokine linked to itch signaling. The therapy provides 6–8 weeks of itch relief, compared with the 4–8 week dosing interval of lokivetmab, the current market-leading therapy
- The USDA approved Befrena in December 2025, making it Elanco’s second monoclonal antibody product in the US pet health market after Trutect. The company has already initiated an Early Experience Program with veterinarians reporting positive outcomes in dogs treated for allergic itch and atopic dermatitis
Why It Matters?
Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits as key selling points.
As the company’s second US monoclonal antibody (after Trutect), the phased launch and Early Experience Program should help Elanco win dermatologist and general‑practice adoption, capture share in chronic allergic and atopic dermatitis, and expand its higher‑margin dermatology franchise while deepening competition in premium, in‑clinic biologic itch control.
Source: PRnewswire
